Corneal biometry changes with 0.01% atropine for myopia control: a randomised controlled trial and case of incidental keratoconus
Abstract
Changes in corneal curvature have been reported with low-concentration atropine eyedrops for myopia treatment and have been suggested to play a role in the refractive changes observed during atropine therapy. A case of keratoconus was identified from the Western Australia atropine for the treatment of myopia (WA-ATOM) cohort. We tested the null hypothesis that 0.01% atropine eyedrops produce no change in corneal parameters or ectasia risk compared to placebo. Children with progressive myopia (6–16 years; n = 153) were randomly assigned to receive 0.01% atropine eyedrops or a placebo (2:1 ratio) for 2 years, followed by a 1-year washout. Scheimpflug imaging was performed at baseline, 24-months, and 36-months. Changes in corneal parameters were compared between the treatment and placebo groups using linear mixed models. One child allocated to the treatment group developed keratoconus during the treatment phase. At 24 and 36 months, the atropine group had significantly lower BAD-D values compared to placebo, with reductions of − 0.075 (95% CI − 0.126 to − 0.023, p = 0.027) and − 0.115 (95% CI − 0.168 to − 0.063, p = 0.005) from baseline, respectively ( p = 0.029 and 0.005). At 36 months, a significant steepening of K max of + 0.301D (95% CI 0.214 to 0.389, p = 0.039) was observed in the atropine group. All other corneal parameters and cylindrical power remained similar between the groups. The case of incidental keratoconus in the treatment group (1 out of 153 children) is compatible with population prevalence rates. No signal suggesting a treatment-related increase in corneal ectatic changes was identified within the limitations of this cohort, and these findings provide reassurance from a safety perspective, but clinicians should be aware of the rare possibility of keratoconus and refer patients with suspicious corneal findings.
Related
- Different concentrations of atropine in children with high myopia: a 2-year multicenter double-blind, randomized controlled trial
- Acupuncture for older adults with dementia in residential care homes: an assessor-blinded, randomised controlled trial
- Standardised procalcitonin monitoring and antibiotic duration in community-acquired sepsis: a pragmatic randomised controlled trial
- Efficacy and Safety of a Novel Oil Pulling Oral Rinse for Teeth Whitening: A Double-Blind, Randomised, Placebo-Controlled Trial
- Effect of nursing care program on healthy lifestyle behaviours and quality of life in women with endometriosis: a randomised controlled trial
BibTeX
@article{soh2026corneal,
title = {{Corneal biometry changes with 0.01% atropine for myopia control: a randomised controlled trial and case of incidental keratoconus}},
author = {Alvid Soh and Gareth Lingham and Elsie Chan and Antony Clark and David A. Mackey and Samantha Sze-Yee Lee},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-74892-8},
url = {https://www.nature.com/articles/s41598-026-74892-8},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Corneal biometry changes with 0.01% atropine for myopia control: a randomised controlled trial and case of incidental keratoconus
AU - Alvid Soh
AU - Gareth Lingham
AU - Elsie Chan
AU - Antony Clark
AU - David A. Mackey
AU - Samantha Sze-Yee Lee
PY - 2026
DA - 2026/10/19
JO - Scientific Reports
DO - 10.1038/s41598-026-74892-8
UR - https://www.nature.com/articles/s41598-026-74892-8
AB - Changes in corneal curvature have been reported with low-concentration atropine eyedrops for myopia treatment and have been suggested to play a role in the refractive changes observed during atropine therapy. A case of keratoconus was identified from the Western Australia atropine for the treatment of myopia (WA-ATOM) cohort. We tested the null hypothesis that 0.01% atropine eyedrops produce no change in corneal parameters or ectasia risk compared to placebo. Children with progressive myopia (6–16 years; n = 153) were randomly assigned to receive 0.01% atropine eyedrops or a placebo (2:1 ratio) for 2 years, followed by a 1-year washout. Scheimpflug imaging was performed at baseline, 24-months, and 36-months. Changes in corneal parameters were compared between the treatment and placebo groups using linear mixed models. One child allocated to the treatment group developed keratoconus during the treatment phase. At 24 and 36 months, the atropine group had significantly lower BAD-D values compared to placebo, with reductions of − 0.075 (95% CI − 0.126 to − 0.023, p = 0.027) and − 0.115 (95% CI − 0.168 to − 0.063, p = 0.005) from baseline, respectively ( p = 0.029 and 0.005). At 36 months, a significant steepening of K max of + 0.301D (95% CI 0.214 to 0.389, p = 0.039) was observed in the atropine group. All other corneal parameters and cylindrical power remained similar between the groups. The case of incidental keratoconus in the treatment group (1 out of 153 children) is compatible with population prevalence rates. No signal suggesting a treatment-related increase in corneal ectatic changes was identified within the limitations of this cohort, and these findings provide reassurance from a safety perspective, but clinicians should be aware of the rare possibility of keratoconus and refer patients with suspicious corneal findings.
SN - 2045-2322
ER -